SmartLung Dx™, entering the final stage of development, is a blood-based assay intended for use as an adjunctive confirmatory test to assess the absence of lung cancer in patients with a history of smoking who have an imaging-detected nodule between 0.8 – 3.0 cm and who are being considered for a downstream invasive procedure.
Driving Healthcare Forward
It is estimated that there are tens of millions of patients in the total addressable global market
The current standard of care is an invasive lung biopsy, or watch-and-wait with multiple scans
SmartLung Dx is a non-invasive blood test that aims to identify lung nodules that are likely benign, enabling patients to avoid potentially risky invasive biopsy procedures
This test is designed to help minimize hospitalizations from lung biopsy complications